Page last updated: 2024-12-06

dermatan sulfate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Dermatan Sulfate: A naturally occurring glycosaminoglycan found mostly in the skin and in connective tissue. It differs from CHONDROITIN SULFATE A (see CHONDROITIN SULFATES) by containing IDURONIC ACID in place of glucuronic acid, its epimer, at carbon atom 5. (from Merck, 12th ed) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S : An oligosaccharide sulfate that is 2-acetamido-2-deoxy-4-O-sulfo-beta-D-galactopyranose in which the hydroxy group at position 3 has been converted to the corresponding alpha-L-idopyranuronoside. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

dermatan sulfate : Any of a group of glycosaminoglycans with repeating units consisting of variously sulfated beta1->4-linked L-iduronyl-(alpha1->3)-N-acetyl-D-galactosamine units. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3032806
CHEMBL ID4071896
CHEBI ID18376
CHEBI ID145592
SCHEMBL ID5790851
MeSH IDM0006045

Synonyms (12)

Synonym
beta-heparin
chondroitin sulfate b
dermatan sulfate
CHEBI:18376
wurcs=2.0/2,2,1/[a2112h-1b_1-5_2*ncc/3=o_4*oso/3=o/3=o][a2121a-1a_1-5]/1-2/a3-b1
2-acetamido-2-deoxy-3-o-alpha-l-idopyranuronosyl-4-o-sulfo-beta-d-galactopyranose
CHEBI:145592
(2r,3s,4s,5r,6r)-6-[(2r,3r,4r,5r,6r)-3-acetamido-2-hydroxy-6-(hydroxymethyl)-5-sulfooxyoxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
idoa(a1-3)b-galnac4s
alpha-l-idopa-(1->3)-beta-d-galpnac4s
SCHEMBL5790851
CHEMBL4071896

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" It was well tolerated and no adverse effects occurred."( Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers.
Dawes, J; Moelker, HC; Stiekema, JC; Toeberich, H; Van Dinther, TG; Vinchenzo, A; Wijnand, HP, 1989
)
0.28
" 1250 anti-Xa Units of Org 10172 once daily is both safe and as effective as 5000 IU of heparin sodium twice daily given for DVT prophylaxis in patients with acute ischaemic stroke of recent onset."( A multicentre, double-blind, randomized study to compare the safety and efficacy of once-daily ORG 10172 and twice-daily low-dose heparin in preventing deep-vein thrombosis in patients with acute ischaemic stroke.
Abedinpour, F; Berberich, R; Dumas, R; Egberts, JF; Gregoire, F; Jerkovic, M; Kutnowski, M; Nikolic, I; Woitinas, F; Zoeckler, S, 1994
)
0.29
"Danaparoid sodium appears to be an efficient and safe treatment in critically ill patients with HIT."( Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.
Guyotat, D; Mahul, P; Mazet, E; Mismetti, P; Reynaud, J; Tardy, B; Tardy-Poncet, B, 1999
)
0.3
"8%) survived, 7 having suffered from a serious adverse event."( Safety and efficacy of danaparoid (Orgaran) use in children.
Bidlingmaier, C; Girisch, M; Kurnik, K; Magnani, HN, 2006
)
0.33

Pharmacokinetics

The pharmacodynamic profile of standard heparin (SH), a low molecular weight derivative (CY 216) and of dermatan sulfate (DS), a new potential antithrombotic drug, was investigated.

ExcerptReferenceRelevance
"In order to improve the pharmacokinetic properties of unfractionated dermatan sulfate (UDS, mean MW: 25kD), the disposition of 4 low molecular weight dermatan sulfates (LMWDS) with a mean MW ranging from 15 to 4 kD was investigated in the rabbit."( Influence of molecular weight upon the anticoagulant and pharmacokinetic properties of dermatan sulfate in the rabbit.
Boneu, B; Caranobe, C; Dol, F; Houin, G; Lormeau, JC; Petitou, M; Saivin, S; Sie, P, 1992
)
0.28
"The pharmacodynamic profile of standard heparin (SH), a low molecular weight derivative (CY 216) and of dermatan sulfate (DS), a new potential antithrombotic drug, was investigated in the rabbit over a large range of doses."( Pharmacokinetics of heparin and related polysaccharides.
Boneu, B; Caranobe, C; Dol, F; Houin, G; Sie, P, 1989
)
0.28
" We investigated the pharmacodynamic and pharmacokinetic properties of DS in humans."( Pharmacodynamics and pharmacokinetics of dermatan sulfate in humans.
Boneu, B; Dol, F; Dupouy, D; Gianese, F; Houin, G; Montastruc, JL; Rostin, M; Sie, P, 1989
)
0.28
"To investigate the pharmacokinetic properties of dermatan sulfate (DS), a new potential antithrombotic agent, two different approaches were used."( Pharmacokinetics of dermatan sulfate in the rabbit after intravenous injection.
Boneu, B; Cadroy, Y; Caranobe, C; Dol, F; Dupouy, D; Gabaig, AM; Houin, G; Mardiguian, J; Sié, P, 1988
)
0.27
"1 years) who had had an acute myocardial infarction within the previous 7 days, were enrolled in an open pharmacodynamic study."( Pharmacodynamic characteristics of low-molecular-weight dermatan sulphate after subcutaneous administration in acute myocardial infarction.
Branzi, A; Candiotti, N; Cervi, V; Melandri, G; Palazzini, E; Semprini, F; Traini, AM; Zamboni, V,
)
0.13
" A one-compartment model for multiple doses was employed to estimate the pharmacokinetic parameters."( Intramuscular dermatan sulfate MF701 in patients with hip fracture: relationship between pharmacokinetics and antithrombotic efficacy.
Agnelli, G; Damiani, M; Dupouy, D; Gianese, F; Houin, G; Imbimbo, BP; Saivin, S; Sié, P, 1994
)
0.29
" The resulting anticoagulant activities were assessed by the activated partial thromboplastin time (aPTT) and the pharmacokinetic parameters were calculated from the plasma concentrations of DS measured by a chromogenic assay."( Pharmacokinetics and pharmacodynamics of dermatan sulfate after intravenous and intramuscular administration to healthy volunteers.
Blardi, P; Di Perri, T; Messa, GL; Urso, R, 1993
)
0.29
"The pharmacodynamic pattern of low molecular weight dermatan sulphate (CAS 24967-94-0, Desmin-LMWDS) was studied in patients presenting chronic renal insufficiency."( Pharmacodynamic study of low molecular weight dermatan sulphate (Desmin) after a single subcutaneous administration in patients with renal insufficiency.
Boneu, B; Duchêne, P; Ducret, F; Houin, G; Palazzini, E; Pourrat, J; Saivin, S; Zamboni, W, 2000
)
0.31

Bioavailability

A Low Molecular Mass Dermatan Sulfate (LMM-DS), endowed with a bioavailability three-four times higher than DS, by subcutaneous route, was obtained by chemical depolymerization of DS. The low molecular weight (Mr) of the constituents of Sulodexide would predict that the product has the high bioavailability associated withLow-Mr heparin and low-Mr dermatan sulfate.

ExcerptReferenceRelevance
" The absolute bioavailability of Orgaran following subcutaneous administration was determined on the basis of plasma anti-Xa and IIaGI activities and the NoA-GAG fraction concentrations."( Pharmacokinetic considerations on Orgaran (Org 10172) therapy.
Danhof, M; de Boer, A; Magnani, HN; Stiekema, JC, 1992
)
0.28
" After subcutaneous administration, the bioavailability of the 4 LMWDS was improved in comparison with that of UDS, but large inter-animal variations were recorded for LMWDS having a mean MW over 9 kD."( Influence of molecular weight upon the anticoagulant and pharmacokinetic properties of dermatan sulfate in the rabbit.
Boneu, B; Caranobe, C; Dol, F; Houin, G; Lormeau, JC; Petitou, M; Saivin, S; Sie, P, 1992
)
0.28
" After intramuscular injection the apparent bioavailability of dermatan sulphate was 16-20%."( The pharmacokinetics of dermatan sulphate MF701 in healthy human volunteers.
Belch, JJ; Bray, B; Dawes, J; Forbes, C; Gianese, F; Houin, G; Lane, DA; McEwen, J; McLaren, M, 1991
)
0.28
" The bioavailability of low molecular weight dermatan sulfate from its subcutaneous depot was 100%; it was absorbed faster from that depot than unfractionated dermatan sulfate."( Pharmacologic properties of a low molecular weight dermatan sulfate: comparison with unfractionated dermatan sulfate.
Boneu, B; Caranobe, C; Choay, J; Dol, F; Houin, G; Lormeau, JC; Petitou, M; Saivin, S; Sie, P, 1990
)
0.28
" The absolute bioavailability of Org 10172 as measured by plasma anti-Xa activity, glycosaminoglycuronans with no affinity to antithrombin III (NoA-GAG) and thrombin generation inhibiting activity approached 100% in both sexes."( Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers.
Dawes, J; Moelker, HC; Stiekema, JC; Toeberich, H; Van Dinther, TG; Vinchenzo, A; Wijnand, HP, 1989
)
0.28
" After SC injection, the bioavailability was less than 50% for U-DS and at least 100% for LMW-DS."( Pharmacological properties of dermatan sulfate, of a low molecular weight dermatan sulfate and of two oversulfated derivatives.
Boneu, B; Choay, J; Dol, F; Houin, G; Petitou, M; Sie, P, 1989
)
0.28
" The estimated plasmatic bioavailability was about 18% for DS."( Human pharmacokinetics of glycosaminoglycans using deuterium-labeled and unlabeled substances: evidence for oral absorption.
Coppini, A; Da Col, R; Ferro, L; Gori, M; Lanzarotti, E; Marchi, E; Milani, MR; Pescador, R; Silvestro, L, 1994
)
0.29
" The reduction in molecular weight significantly enhanced the bioavailability of the product after subcutaneous administration."( Preliminary chemical, biochemical, and pharmacological characterization of a low molecular weight dermatan sulphate.
Ferrari, GP; Maggi, AP; Marchesini, D, 1994
)
0.29
" A Low Molecular Mass Dermatan Sulfate (LMM-DS), endowed with a bioavailability three-four times higher than DS, by subcutaneous route, was obtained by chemical depolymerization of DS."( Active site for heparin cofactor II in low molecular mass dermatan sulfate. Contribution to the antithrombotic activity of fractions with high affinity for heparin cofactor II.
Bergonzini, G; Bianchini, P; Liverani, L; Mascellani, G; Parma, B, 1996
)
0.29
" The low molecular weight (Mr) of the constituents of Sulodexide would predict that the product has the high bioavailability associated with low-Mr heparin and low-Mr dermatan sulfate."( Pharmacological actions of sulodexide.
Ofosu, FA, 1998
)
0.3
" The advantages of LMW heparins over unfractionated heparin include a longer half-life (allowing once-daily or twice-daily subcutaneous dosing), high bioavailability and predictable anticoagulant response (avoiding the need for dose adjustment or laboratory monitoring in most patients), and a low risk of heparin-induced thrombocytopenia and osteoporosis."( Low molecular weight heparins and heparinoids.
Eikelboom, JW; Hankey, GJ, 2002
)
0.31
" Synthetic, selective, and direct inhibitors to FXa, such as DX-9065a, are highly potent and orally bioavailable antithrombotic agents that have demonstrated an improved side effect profile, probably by allowing sufficient thrombin to remain for platelet activation and normal hemostasis, while preventing pathological thrombus formation."( Factor Xa inhibitors: new anti-thrombotic agents and their characteristics.
Ieko, M; Koike, T; Naito, S; Nakabayashi, T; Tarumi, T; Yoshida, M, 2006
)
0.33
" Fondaparinux has excellent bioavailability when administered subcutaneously, has a longer half-life than LMWHs, and is given once daily by subcutaneous injection in fixed doses, without anticoagulant monitoring."( Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Bauer, KA; Donati, MB; Gould, M; Hirsh, J; Samama, MM; Weitz, JI, 2008
)
0.35
" It seems that fascia fibrosis process when compared with physiological circumstances is associated with the preservation of at least some functions of decorin and biglycan DSs such as the regulation of growth factor bioavailability and most probably influence FN fibrillogenesis as well as coupling of various fibrilar matrix element assembly."( The role of decorin and biglycan dermatan sulfate chain(s) in fibrosis-affected fascia.
Koźma, EM; Kusz, D; Olczyk, K; Wisowski, G, 2011
)
0.37
" Fondaparinux exhibits complete bioavailability when administered subcutaneously, has a longer half-life than LMWHs, and is given once daily by subcutaneous injection in fixed doses, without coagulation monitoring."( Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Baglin, TP; Garcia, DA; Samama, MM; Weitz, JI, 2012
)
0.38

Dosage Studied

Dosing of 100 mg LMW-dermatan sulfate did not modify TFPI, coagulation or fibrinolytic parameters. Linear dose-response relationships were observed between the level of arginine amidase activity released from the isolated rabbit ear artery and aorta.

ExcerptRelevanceReference
" Rapid elimination of some of these components may explain why twice daily dosing is required for optimal thrombosis prophylaxis with Orgaran."( Pharmacokinetic considerations on Orgaran (Org 10172) therapy.
Danhof, M; de Boer, A; Magnani, HN; Stiekema, JC, 1992
)
0.28
" The studies have established a potentially optimal dosage and treatment regimen and have provided information for the development of a large randomized trial."( Studies of Org 10172 in patients with acute ischemic stroke. TOAST Study Group.
Adams, HP; Biller, J; Clarke, W; Woolson, RF, 1992
)
0.28
" In the presence of Org 10172 there was a reduction in the AUC of digoxin during one dosing interval after the seventh digoxin tablet from 20 to 17 ng."( Interaction of ORG 10172, a low molecular weight heparinoid, and digoxin in healthy volunteers.
Breimer, DD; Danhof, M; de Boer, A; Moolenaar, AJ; Stiekema, JC, 1991
)
0.28
" Increasing concentrations of macrophage-conditioned media were associated with a dose-response increase in [35S]sulfate incorporation into secreted proteoglycans, but there was no change in cell-associated proteoglycans."( Macrophage secretory products selectively stimulate dermatan sulfate proteoglycan production in cultured arterial smooth muscle cells.
Edwards, IJ; Owens, RT; Wagner, WD, 1990
)
0.28
" However, allergen-induced release of GAG from the basophils of atopic individuals exhibited a different time-course and dose-response from that of histamine, and may occur at least in part by a different mechanism."( Release of highly-sulphated glycosaminoglycans and histamine from human basophils.
Barnetson, RS; Dawes, J; MacGregor, IR; Reilly, KM; Yap, PL, 1988
)
0.27
" Since there was no apparent dose effect gradient, it was decided to pool the data from all three dosing blocks: this analysis showed that Org 10172 increased geometric mean blood loss during the first 2 days after surgery from 10."( The influence of Org 10172, an antithrombotic heparinoid, on urinary blood loss after transurethral prostatectomy.
Gallus, A; Magnani, H; Marshall, V; Morris, M; Murphy, W; Nacey, J; Sutherland, P, 1989
)
0.28
"4 unit Org 10172 dosage was as effective as heparin in preventing fibrin deposition."( Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients.
Büller, HR; Henny, CP; Mooy, MC; Surachno, S; ten Cate, H; ten Cate, JW; Wilmink, JM, 1985
)
0.27
" Consecutive patients aged forty years or more, electively undergoing total hip replacement under general anaesthesia, were randomly allocated to one of three dosage regimens of dermatan sulphate (MF701, Mediolanum Farmaceutici) given intramuscularly."( A dose ranging study to evaluate dermatan sulphate in preventing deep vein thrombosis following total hip arthroplasty.
Cohen, AT; Cooper, DJ; Das, SK; Edmondson, RA; Kakkar, VV; Melissari, E; Phillips, MJ; Skinner, JA; Thomas, EM, 1994
)
0.29
" Both recombinant IL-1 alpha and IL-1 beta caused a dose-response increase in DSPG production."( Interleukin-1 upregulates decorin production by arterial smooth muscle cells.
Edwards, IJ; Wagner, WD; Wright, MJ; Xu, H, 1994
)
0.29
" Heparin therapy adapted to the result of the activated cephalin time (two to three times the control value) and oral vitamin K antagonists with a dosage adapted to keep the International Normalized Ratio between 2 and 3 is the safest and most effective treatment to date."( [Anticoagulant therapy in pulmonary embolism].
Augusseau-Richard, MP; Charbonnier, B; Dessenne, X; Pacouret, G; Pagot, O, 1995
)
0.29
" dosing of 100 mg LMW-dermatan sulfate did not modify TFPI, coagulation or fibrinolytic parameters."( Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers.
Acker, M; Harenberg, J; Heene, DL; Huhle, G; Jeschek, M; Malsch, R, 1996
)
0.29
" Exact dosage schedules are provided."( [Loss of extremities caused by heparin-induced thrombocytopenia].
Leffringhausen, W; Scherlitzky, L; Wenzl, ME, 1996
)
0.29
" Danaparoid, a low-molecular-weight heparinoid, and once-daily enoxaparin are recently released dosage forms that have been evaluated as pharmacoprophylaxis for DVT after hip replacement surgery."( Cost effectiveness of danaparoid compared with enoxaparin as deep vein thrombosis prophylaxis after hip replacement surgery.
Wade, WE, 1999
)
0.3
" Dose-response experiments were also performed with the polycationic (positively charged) polysaccharide chitosan covalently coupled to agarose."( The polarity and magnitude of ambient charge influences three-dimensional neurite extension from DRGs.
Bellamkonda, RV; Dillon, GP; Yu, X, 2000
)
0.31
" All agents were supplemented to the citrated-pooled plasma prepared from 10 healthy volunteers at a graded dosage of 0 to 100 microg/ml."( Ecarin clotting time is sensitive to heparinoids: comparison of two different techniques.
Demir, M; Fareed, J; Gaikwad, BS; Hoppensteadt, DA; Iqbal, O; Untch, B, 2001
)
0.31
"The effects of dosing time on the anticoagulant activity of unfractionated heparin, low molecular weight heparin (nadroparin) and danaproid were investigated."( A chronopharmacodynamic study on standard heparin, a low molecular weight heparin (nadroparin) and danaproid: establishing and comparing the daily variations of these drugs in rats.
Abrial, D; Blanc, A; Bouchut, C; Buisson, B; Decousus, H; Laporte-Simitsidis, S; Mismetti, P; Réhailia, M,
)
0.13
" Linear dose-response relationships were observed between the level of arginine amidase activity released from the isolated rabbit ear artery and aorta and the concentration of dermatan sulfate added."( Effects of dermatan and dextran sulfates on arginine amidase activity released from isolated rabbit arteries.
Chiba, R; Ishii-Nozawa, R; Katayama, M; Matsuda, Y; Miyazaki, K; Shimokawa, K; Takeuchi, K, 2001
)
0.31
" The present tendency is to do without biological monitoring for adapting dosage in favour of optimisation of the impact in a given situation, perhaps, above all, with respect to the preceding problem."( [New antithrombotic drugs (excluding plasminogen activators].
Lecompte, T, 2001
)
0.31
" However, optimal dosing regimens have not been established in all cases."( Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia.
Jeske, WP; Walenga, JM, 2002
)
0.31
" Two studies have compared danaparoid with UFH in the prophylaxis of DVT following acute ischaemic stroke; twice daily danaparoid was significantly superior to UFH whereas there was no significant difference between a once-daily dosage and UFH."( Danaparoid: a review of its use in thromboembolic and coagulation disorders.
Ibbotson, T; Perry, CM, 2002
)
0.31
"It is emphasized that the possibility of clinically significant antibody cross-reactivity and that low or intermediate dosage may be inadequate when using danaparoid in therapy of HIT."( Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures.
Kodityal, S; Manhas, AH; Rice, L; Udden, M, 2003
)
0.32
" If the pretest probability of HIT is high, heparin should be stopped and an alternative anticoagulant started at full dosage unless there are significant contraindications while laboratory tests are performed."( The management of heparin-induced thrombocytopenia.
Davidson, S; Keeling, D; Watson, H, 2006
)
0.33
" Clinical outcomes of these case reports of patients given danaparoid because of suspected or confirmed HIT appear to be comparable with those reported by others who used direct thrombin inhibitors, especially when a sufficient danaparoid dosing intensity was used in patients with isolated HIT."( Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004.
Gallus, A; Magnani, HN, 2006
)
0.33
" Recent data indicate that the approved dosing regimens of the direct thrombin inhibitors are too high, especially in ICU patients."( Heparin-induced thrombocytopenia in intensive care patients.
Greinacher, A; Selleng, K; Warkentin, TE, 2007
)
0.34
" Important drug-specific limitations and dosing and monitoring guidelines must be respected for patient safety."( The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update.
Prechel, M; Walenga, JM, 2008
)
0.35
" When dosed back onto cells exogenously in soluble form, GAGs regulated MG-63 survival and growth in a dose-dependent manner, but not differentiation in either cell type."( Glycosaminoglycan composition changes with MG-63 osteosarcoma osteogenesis in vitro and induces human mesenchymal stem cell aggregation.
Cool, SM; Kumarasuriyar, A; Murali, S; Nurcombe, V, 2009
)
0.35
" However, before attributing thrombotic complications to danaparoid cross-reactivity, it is crucial to verify that the patients received the recommended danaparoid dosage regimen."( Danaparoid cross-reactivity with heparin-induced thrombocytopenia antibodies: report of 12 cases.
Bauters, A; Elalamy, I; Ffrench, P; Lasne, D; Tardy, B; Tardy-Poncet, B; Wolf, M, 2009
)
0.35
"5% pregnancies respectively at a dosing intensity of 1000 to 7500 U/day."( An analysis of clinical outcomes of 91 pregnancies in 83 women treated with danaparoid (Orgaran).
Magnani, HN, 2010
)
0.36
" The treatment started with a smaller therapeutic doses of danaparoid than recommended of 750 U intravenous bolus and was followed by continuous infusions of 100 U per 1 h and intravenous gammaglobulins in full dosage for four days."( [Heparin-induced thrombocytopenia occurring after surgical treatment of atrial myxoma--a case report].
Antonijević, N; Djunić, I; Djurasinović, V; Elezović, I; Gradinac, S; Kovac, M; Tomin, D; Vidović, A,
)
0.13
" At concentrations higher than the "therapeutic" levels, the dose-response curve in the Ks assay became very steep for lepirudin while those were shallow for the others."( The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis.
Bark, N; Blombäck, M; He, S; Johnsson, H; Wallén, NH, 2010
)
0.36
"Anticoagulation by a standard dosage of an inhibitor of thrombin generation presupposes predictable pharmacokinetics and pharmacodynamics of the anticoagulant."( Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation.
Al Dieri, R; Bloemen, S; Hemker, HC, 2013
)
0.39
" The persistency of the residual amounts of DS with the actually recommended dosage in our Patient may suggest the opportunity to promote further studies with increased enzyme dosages to completely remove the accumulation of lysosomal DS."( Plasmatic kinetics of dermatan sulfate during enzyme replacement therapy with iduronate-2-sulfatase in a mucopolysaccharidosis II patient.
Coppa, GV; Gabrielli, O; Galeazzi, T; Galeotti, F; Maccari, F; Santoro, L; Volpi, N; Zampini, L, 2013
)
0.39
" Danaparoid is an alternative anticoagulant used in patients on HD with HIT but its dosing recommendations in obese patients on HD are relatively scarce."( Danaparoid use for haemodialysis in a morbidly obese patient with heparin-induced thrombocytopenia - Need for a higher than recommended weight-based dosing.
Castelino, RL; Kairaitis, L; Maddula, M; Sud, K; Tarafdar, S, 2019
)
0.51
"We report a case of a 48-year-old morbidly obese patient who received weight-based dosing of danaparoid for HD with monitoring of anti-Xa activity."( Danaparoid use for haemodialysis in a morbidly obese patient with heparin-induced thrombocytopenia - Need for a higher than recommended weight-based dosing.
Castelino, RL; Kairaitis, L; Maddula, M; Sud, K; Tarafdar, S, 2019
)
0.51
"The report provides evidence that the manufacturer's recommendations on dosing danaparoid based on body weight may lead to sub-optimal therapeutic benefit and highlight the need for higher than recommended weight-based dosing in obese individuals on dialysis."( Danaparoid use for haemodialysis in a morbidly obese patient with heparin-induced thrombocytopenia - Need for a higher than recommended weight-based dosing.
Castelino, RL; Kairaitis, L; Maddula, M; Sud, K; Tarafdar, S, 2019
)
0.51
" In addition to clinical monitoring, GAG dosage has been commonly used to evaluate ERT efficacy."( Glycosaminoglycan signatures in body fluids of mucopolysaccharidosis type II mouse model under long-term enzyme replacement therapy.
Capitani, F; D'Avanzo, F; Gabrielli, O; Galeotti, F; Maccari, F; Mantovani, V; Rigon, L; Salvalaio, M; Tomanin, R; Volpi, N; Zanetti, A, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
glycosylgalactose derivativeA disaccharide derivative that is formally obtained from a glycosylgalactose.
amino disaccharideA disaccharide derivative that is a disaccharide having one or more substituted or unsubstituted amino groups in place of hydroxy groups at unspecified positions.
oligosaccharide sulfateAny carbohydrate sulfate that is an oligosaccharide carrying at least one O-sulfo substituent.
iduronic acids
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Glycosaminoglycan degradation02
Glycosaminoglycan synthesis in fibroblasts011

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,467)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990732 (29.67)18.7374
1990's744 (30.16)18.2507
2000's549 (22.25)29.6817
2010's360 (14.59)24.3611
2020's82 (3.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials100 (3.91%)5.53%
Reviews217 (8.49%)6.00%
Case Studies185 (7.24%)4.05%
Observational2 (0.08%)0.25%
Other2,053 (80.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]